Bristol Myers Squibb (BMY) reported strong third-quarter earnings, exceeding revenue and earnings per share estimates. The company’s Growth Portfolio, particularly Reblozyl, Breyanzi, Camzyos, and Opdualag, drove significant growth. Eliquis sales also saw a substantial increase, while the Legacy Portfolio performed well despite generic competition for Sprycel. Bristol Myers Squibb is optimistic about the future, forecasting revenue growth and cost savings, and is currently launching its new schizophrenia treatment, Cobenfy.